Skip to main content

Advertisement

SpringerLink
Log in

Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination

  • Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95. doi:10.2337/db09-9028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cherrington AD. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–214.

    Article  CAS  PubMed  Google Scholar 

  3. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 2000;43:946–52.

    Article  CAS  PubMed  Google Scholar 

  4. Chap Z, Ishida T, Chou J, Hartley CJ, Entman ML, Brandenburg D, et al. First-pass hepatic extraction and metabolic effects of insulin and insulin analogues. Am J Physiol. 1987;252:E209–17.

    CAS  PubMed  Google Scholar 

  5. Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol. 1990;258(6 Pt 1):E1020–32.

    CAS  PubMed  Google Scholar 

  6. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90:1323–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.

    Article  CAS  PubMed  Google Scholar 

  8. Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res. 2001;56:219–37.

    Article  CAS  PubMed  Google Scholar 

  9. Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63:494–504. doi:10.2337/db13-0826.

    Article  CAS  PubMed  Google Scholar 

  10. Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, et al. Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64:3439–51. doi:10.2337/db15-0071.

    Article  CAS  PubMed  Google Scholar 

  11. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev. 2006;22:274–83.

    Article  CAS  PubMed  Google Scholar 

  12. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis. 2007;17:63–70.

    Article  PubMed  Google Scholar 

  13. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol. 1989;8:107–14.

    Article  CAS  PubMed  Google Scholar 

  14. Merli M, Leonetti F, Riggio O, Valeriano V, Ribaudo MC, Strati F, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology. 1999;30:649–54.

    Article  CAS  PubMed  Google Scholar 

  15. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637–53. doi:10.1016/j.bpg.2014.07.008.

    Article  CAS  PubMed  Google Scholar 

  16. Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–38. doi:10.3390/nu7115454.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20:9072–89. doi:10.3748/wjg.v20.i27.9072.

    PubMed  PubMed Central  Google Scholar 

  18. Huang J, Karnchanasorn R, Ou HY, Feng W, Chuang LM, Chiu KC, et al. Association of insulin resistance with serum ferritin and aminotransferases-iron hypothesis. World J Exp Med. 2015;5:232–43. doi:10.5493/wjem.v5.i4.232.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931–9.

    Article  CAS  PubMed  Google Scholar 

  20. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002;51:1000–4.

    Article  CAS  PubMed  Google Scholar 

  21. Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet. 2015;24:R85–92. doi:10.1093/hmg/ddv264. This article provides the complex insight of genetics of type 2 diabetes.

    Article  CAS  PubMed  Google Scholar 

  22. Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care. 2014;37:943–9. doi:10.2337/dc13-1954.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–6.

    Article  CAS  PubMed  Google Scholar 

  24. Huang J, Ou HY, Lin J, Karnchanasorn R, Feng W, Samoa R, et al. The impact of hepatitis B vaccination status on the risk of diabetes, implicating diabetes risk reduction by successful vaccination. PLoS One. 2015;10(10):e0139730. doi:10.1371/journal.pone.0139730. This article provides the first evidence that diabetes could be prevented from hepatitis B vaccination.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800. doi:10.1016/j.diabres.2013.11.002. This article provides the detailed epidemiological information on viral hepatitis and diabetes.

    Article  Google Scholar 

  26. Jacobsen KH, Wiersma ST. Hepatitis a virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.

    Article  PubMed  Google Scholar 

  27. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.

    Article  PubMed  Google Scholar 

  28. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.

    Article  PubMed  Google Scholar 

  29. Viral hepatitis. 2016. http://www.cdc.gov/hepatitis/ Accessed on April 1, 2016

  30. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607. doi:10.1056/NEJMoa1512610.

    Article  CAS  PubMed  Google Scholar 

  31. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17. doi:10.1056/NEJMoa1512612.

    Article  CAS  PubMed  Google Scholar 

  32. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98. doi:10.1056/NEJMoa1402454.

    Article  PubMed  Google Scholar 

  33. National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States. Washington, DC: National Academies Press, April 11, 2016. https://www.nationalacademies.org/hmd/Reports/2016/Eliminating-the-Public-Health-Problem-of-Hepatitis-B-and-C-in-the-US.aspx. This book provides the detailed information on both hepatitis B and C.

  34. Buckley GJ, Strom BL. What stands in the way of making hepatitis B and C rare diseases in the United States? Ann Intern Med. 2016. doi:10.7326/M16-0772.

    PubMed  Google Scholar 

  35. Hwang YC, Jeong IK, Chon S, Oh S, Ahn KJ, Chung HY, et al. Fulminant type 1 diabetes mellitus associated with acute hepatitis A. Diabet Med. 2010;27:366–7. doi:10.1111/j.1464-5491.2010.02930.x.

    Article  PubMed  Google Scholar 

  36. Atabek ME, Kart H, Erkul I. Prevalence of hepatitis A, B, C and E virus in adolescents with type-1 diabetes mellitus. Int J Adolesc Med Health. 2003;15:133–7.

    Article  PubMed  Google Scholar 

  37. Vesely DL, Dilley RW, Duckworth WC, Paustian FF. Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Am J Med Sci. 1999;317:419–24.

    Article  CAS  PubMed  Google Scholar 

  38. Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the Multiethnic Study of Atherosclerosis. Diabet Med. 2009;26:149–52. doi:10.1111/j.1464-5491.2008.02632.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Oli JM, Nwokolo C. Diabetes after infectious hepatitis: a follow-up study. Br Med J. 1979;7;1(6168):926–7.

    Article  Google Scholar 

  40. Chupin M, Charbonnel B, Le BL, Grolleau JY, Chupin F, Guillon J. Glucose tolerance in viral hepatitis. A study of twenty patients during the acute phase and after recovery. Diabetes. 1978;27:661–9.

    Article  CAS  PubMed  Google Scholar 

  41. Adi FC. Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria. Br Med J. 1974;1(5900):183–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279–83.

    Article  CAS  PubMed  Google Scholar 

  43. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005;28:2548–50.

    Article  PubMed  Google Scholar 

  44. Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–43.

    Article  PubMed  Google Scholar 

  45. Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol. 2003;38:355–60.

    Article  PubMed  Google Scholar 

  46. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28(3):355–62.

    Article  CAS  PubMed  Google Scholar 

  47. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203.

    Article  PubMed  Google Scholar 

  48. Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13(5):303–10.

    Article  CAS  PubMed  Google Scholar 

  49. Spradling PR, Simons B, Narayanan M, Xing J, Homan C, Bulkow L, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection. J Viral Hepat. 2013;20(7):510–3.

    Article  CAS  PubMed  Google Scholar 

  50. Huang ZS, Huang TS, Wu TH, Chen MF, Hsu CS, Kao JH. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol. 2010;25(8):1420–5.

    Article  PubMed  Google Scholar 

  51. Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, et al. Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology. 2015;62(5):1364–74.

    Article  CAS  PubMed  Google Scholar 

  52. Zhang J, Shen Y, Cai H, Liu YM, Qin G. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: a meta-analysis. Hepatol Res. 2015;45(11):1100–9.

    Article  PubMed  Google Scholar 

  53. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut. 2011;60(8):1139–51.

    Article  CAS  PubMed  Google Scholar 

  54. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. [comment in: Ann intern Med. 2000 Oct 17;133(8):650-1]. Ann Intern Med. 2000;133(8):592–9.

    Article  CAS  PubMed  Google Scholar 

  55. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38(1):50–6.

    Article  PubMed  Google Scholar 

  56. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48(2):105–11.

    Article  CAS  PubMed  Google Scholar 

  57. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18(14):1642–51.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Simo R, Lecube A, Genesca J, Esteban JI, Hernandez C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29(11):2462–6.

    Article  PubMed  Google Scholar 

  60. Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, Gonzalez-Moreno EI, Villarreal-Perez JZ, Maldonado-Garza HJ. Current concepts in diabetes mellitus and chronic liver disease: clinical outcomes, hepatitis C virus association, and therapy. Dig Dis Sci. 2015;13.

  61. Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61(2):636–45.

    Article  CAS  PubMed  Google Scholar 

  62. Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol. 2008;103(10):2481–7.

    Article  PubMed  Google Scholar 

  63. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.

    Article  CAS  PubMed  Google Scholar 

  64. Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60(4):1139–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat. 2012;19(5):341–5.

    Article  CAS  PubMed  Google Scholar 

  66. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30(5):750–8.

    Article  CAS  PubMed  Google Scholar 

  67. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;270(24):2931–4.

    Article  CAS  PubMed  Google Scholar 

  68. Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–6.

    Article  CAS  PubMed  Google Scholar 

  69. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844–50.

    Article  CAS  PubMed  Google Scholar 

  70. Reddy MB, Clark L. Iron, oxidative stress, and disease risk. Nutrition Rev. 2004;62(3):120–4.

    Article  Google Scholar 

  71. Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssonen K, Salonen JT. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med. 2003;35(8):922–8.

    Article  CAS  PubMed  Google Scholar 

  72. Wang XH, Cheng PP, Jiang F, Jiao XY. The effect of hepatitis B virus infection on hepcidin expression in hepatitis B patients. Ann Clin Lab Sci. 2013;43(2):126–34.

    CAS  PubMed  Google Scholar 

  73. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology. 1998;28(5):1398–401.

    Article  CAS  PubMed  Google Scholar 

  74. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28(4):940–1.

    Article  PubMed  Google Scholar 

  75. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096–101.

    Article  CAS  PubMed  Google Scholar 

  76. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.

    Article  CAS  PubMed  Google Scholar 

  77. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.

    Article  PubMed  Google Scholar 

  78. Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes Care. 2014;37(9):2557–64.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge an unrestricted research grant from the Jie Chan Chen Foundation to Horng-Yih Ou, MD, PhD. We are in debt to Sarah T. Wilkinson, PhD, for the critical reading and editing of the manuscript; Henry Lin, PhD, for the excellent support of manuscript preparation; and Karen Ramos for the excellent logistic and administrative support of this research endeavor.

Author information

Author notes

    Authors and Affiliations

    1. Division of Endocrinology, Metabolism and Genetics, Department of Internal Medicine, University of Kansas Medical Center, Kansas, KS, USA

      Rudruidee Karnchanasorn

    2. Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng-Kung University Medical College and Hospital, Tainan, Taiwan

      Horng-Yih Ou

    3. Department of Gastroenterology, City of Hope National Medical Center, Duarte, CA, USA

      James Lin

    4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

      Lee-Ming Chuang

    5. Graduate Institute of Preventive Medicine, School of Public Health, National Taiwan University, Taipei, Taiwan

      Lee-Ming Chuang

    6. Department of Clinical Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, Duarte, CA, 91010-3000, USA

      Ken C. Chiu

    7. Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA

      Ken C. Chiu

    Authors
    1. Rudruidee Karnchanasorn
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Horng-Yih Ou
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. James Lin
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Lee-Ming Chuang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Ken C. Chiu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Ken C. Chiu.

    Ethics declarations

    Conflict of Interest

    Rudruidee Karnchanasorn, Horng-Yih Ou, James Lin, Lee-Ming Chuang, and Ken C. Chiu declare that they have no conflicts of interest.

    Human and Animal Rights and Informed Consent

    This review article does not contain any new studies with human or animal subjects performed by any of the authors.

    Additional information

    This article is part of the Topical Collection on Lifestyle Management to Reduce Diabetes/Cardiovascular Risk

    Rudruidee Karnchanasorn, Horng-Yih Ou and James Lin contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Karnchanasorn, R., Ou, HY., Lin, J. et al. Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination. Curr Diab Rep 16, 101 (2016). https://doi.org/10.1007/s11892-016-0790-y

    Download citation

    • Published:

    • DOI: https://doi.org/10.1007/s11892-016-0790-y

    Keywords

    Search

    Navigation